#China #Shenzhen #Kexing Biopharm #GB10 #Ophthalmic Drug

Kexing Biopharm's Innovative GB10: A New Hope in Ophthalmic Treatment

Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm, has made headlines in the pharmaceutical industry with the recruitment and dosing of its first subject in the Phase I clinical trial of GB10 Injection, an innovative ophthalmic drug designed to combat neovascular age-related macular degeneration (nAMD). This critical advancement reflects Kexing's commitment to improving ocular health, particularly for the aging population.

Understanding GB10 and Its Development

GB10 is a high-concentration protein ophthalmic formulation that employs a bisepecific antibody approach to target both VEGF (vascular endothelial growth factor) and Ang-2 (angiopoietin-2). With an impressive concentration of 140 mg/ml, the formulation allows for a reduced volume of injection or higher dosing options, enabling clinicians to extend dosage intervals. This development could facilitate treatment administration once every four months, significantly enhancing patient compliance.

In preclinical studies, GB10 Injection demonstrated competitive biological activity and efficacy compared to existing therapies. Notably, in a model of choroidal neovascularization induced by laser in monkeys, the drug effectively inhibited pathological ocular neovascularization, showcasing its potential as a groundbreaking treatment option.

The Urgent Need for Innovative Treatments

Age-related macular degeneration remains a leading cause of blindness worldwide for individuals over 50. Increasing screen time, coupled with a growing elderly population, has created a surge in demand for effective ocular treatments. Current treatment regimens often require frequent injections, which can negatively impact adherence and overall patient health outcomes. Therefore, delayed dosage intervals offered by GB10 could address these critical clinical challenges by improving treatment adherence and reducing patient burden.

Kexing Biopharm's Broader Strategy and Vision

Kexing Biopharm is not resting on its laurels with GB10; they are simultaneously ramping up research and development efforts for double-target ophthalmic antibodies. The company is also actively pursuing the introduction of other externally developed ophthalmic products into international markets. These include biosimilars of aflibercept and olopatadine hydrochloride eye drops, as part of a comprehensive strategy to expand their global footprint and drive international growth through constant innovation.

Looking forward, Kexing Biopharm is committed to its guiding philosophy: "Precise products for predictable effects and health protection." This commitment positions them to provide high-quality therapeutic options while addressing the ever-evolving needs of patients worldwide.

As the company continues to develop innovative solutions like GB10, the future of ophthalmic care seems increasingly promising. Patients and healthcare providers eagerly await the outcomes of the ongoing clinical trials, hopeful for a new breakthrough in the battle against vision impairment and blindness.

Conclusion

Kexing Biopharm's innovative approach with GB10 not only highlights their dedication to advancing ophthalmic therapies but also emphasizes the urgent need for effective treatments for age-related conditions. The success of the Phase I trial could mark a significant turning point in the management of nAMD and improve the quality of life for millions of individuals at risk of vision loss.